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The aim of this study was to evaluate the quality of five different solid formulations of carbamazepine. The 
reference formulation was Tegretol® 200.00 mg (Novartis) and the others were: generic formulation of 
carbamazepine 200.00 mg (National Industry), similar formulation of carbamazepine 200.00 mg (National 
Industry), and two formulations of carbamazepine 200.00 mg acquired from two different compounding 
pharmacies. The latter consisted of capsules obtained in Natal, the capital city of the Brazilian State of 
Rio Grande do Norte. The quality of samples was evaluated through physical and physical-chemical 
tests, including: weight, diameter, thickness, content, dissolution, disintegration, hardness, friability and 
moisture. The results of friability analysis showed that all formulations met Brazilian and United States 
Pharmacopeia (USP) specifications. In spite of having a higher hardness compared to the reference, 
the generic formulation had a lower disintegration time. This could be associated to the presence of 
crospovidone in its formulation. Results of this study showed that all formulations had dissolutions 
which were in accordance with Brazilian Pharmacopoeia specifications, and quality control tests. An 
exception was found for the similar formulation, which had a hardness parameter that exceeded the 
USP standard. However, this difference was not significant given the similar formulation’s satisfactory 
disintegration time.
Uniterms: Carbamazepine. Medicines/quality control. Generic medicines. Similar medicines. Medicines/
magistral formulation.
O objetivo desse trabalho foi avaliar a qualidade de cinco formulações de carbamazepina na dosagem 
de 200,00 mg: medicamento referência Tegretol® (Novartis), medicamento genérico (indústria nacional), 
medicamento similar (indústria nacional) e cápsulas do mesmo medicamento obtidas de duas farmácias 
de manipulação da cidade do Natal, RN. Os ensaios realizados foram: peso médio, diâmetro, espessura, 
teor, dissolução, desintegração, dureza, friabilidade e umidade. Foi observado que nenhuma das amostras 
analisadas apresentou friabilidade superior ao limite máximo determinado pela Farmacopéia Americana 
(1,5%). O medicamento genérico, apesar de apresentar dureza superior em relação ao medicamento 
de referência, desintegrou em menor tempo, o que pode estar relacionado à crospovidona presente na 
formulação. As amostras analisadas atenderam às especificações da Farmacopéia Brasileira no que 
diz respeito à dissolução. Em geral, os resultados das amostras A, B, C, D e E foram considerados 
satisfatórios uma vez que atenderam as especificações farmacopéicas. Embora a apresentação similar 
não tenha atendido ao padrão USP no que diz respeito à dureza, esse dado não se mostrou significativo, 
uma vez que o tempo de desintegração foi satisfatório.
Unitermos: Carbamazepina. Medicamentos/controle de qualidade. Medicamento genérico. Medicamentos 
similares. Medicamentos/formulação magistral.
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INTRODUCTION
The efficacy of carbamazepine efficacy was confirmed 
in the 1960s, when it was launched in the commercial market. 
It was used as an antiepileptic for the first time in the United 
States in 1974. Carbamazepine was initially prescribed for adult 
patients, and later indicated for use in children. Carbamazepine 
is considered one of the best anticonvulsivant, producing less 
psychological alterations and behavior effects (Castro et al., 
2001). Carbamazepine is used in the treatment of trigeminal and 
glossopharyngeal nerve neuralgia, acting by reducing repetitive 
activation of the action potential (Goodman, Gilman, 2003).
This molecule shows unique pharmacokinetic properties 
giving it a low solubility in water (below 200.00 µg/mL). After 
oral administration, it has a slow rate absorption which requires 
the use of a relatively large dose (Ambrogi et al., 2007).
Currently, several commercial presentations of carbam-
azepine are available in Brazil. Based on their source, they can 
be divided into reference, generic, similar and those produced 
in compounding pharmacies. According to Brazilian law 9.787, 
published in February 10th of 1999, reference medicines are those 
commercialized under registration in Brazil. Reference medi-
cines contain the original drug, which was rigorously developed 
and investigated, and have been submitted to pre-clinical and 
clinical studies for evaluation of their safety and therapeutic 
efficacy (Yacubian, 2007).
Generic medicines have been in use in the United States 
and Europe since 1960. They can have a different formulation 
compared to the reference medicine, but must present the same 
dose, route of administration and presentation as the reference 
(Baracho, 2008). In addition, generics must have the same 
pharmaceutical equivalence and bioequivalence as the reference 
medicine. This must be attested by the regulatory agency of each 
country. In Brazil, this role is performed by the National Health 
Surveillance Agency (ANVISA) (Storpirtis et al., 2004). The 
bioequivalence guarantees that two presentations will have the 
same drug absorption rate and quantity and hence bioavailability 
(Yacubian, 2007).
The similar medicine is the form having the same drug, 
dose, pharmaceutical form, route of administration, dosage and 
indication as the reference medicine, but which has not necessar-
ily been submitted to equivalence and bioequivalence studies.
The medicines acquired from compounding pharmacies 
are normally in capsule form. This pharmaceutical form permits 
a custom dosage of the drug, which reduces the cost compared 
to an industrialized medicine, and also facilitates acquisition of 
the medicine. The capsules also provide a means of obtaining 
a medicine that does not exist in the pharmaceutical market 
(Azevedo, Ribeiro, Araújo, 2008).
The aim of this study was to evaluate the physical and 
physical-chemical quality control of five formulations of 
carbamazepine, namely: a generic presentation, a similar pre-
sentation, and two presentations acquired from two different 
compounding pharmacies.
MATERIALS AND METHODS
Materials
A carbamazepine standard was acquired from Cristália 
Laboratory (Sao Paulo). The methanol used was purchased from 
Merck (Germany) and the sodium sulfate lauryl from Cromato 
Produtos Químicos Ltda. (São Paulo). Two formulations of 
carbamazepine were acquired from two different compound-
ing pharmacies in Natal, Rio Grande do Norte, Brazil. Besides 
these two formulations, Tegretol® 200.00 mg (Novartis) as the 
reference medicine, a generic formulation of carbamazepine 
200.00 mg (National Industry) and a similar formulation of 
carbamazepine 200.00 mg (National Industry), were also used 
as shown in Table I. 
Instrumentation
The following devices were used in the analysis: an 
analytical balance Ohaus® Adventurer model, digital caliper 
Mitutoyo®, spectrophotometer Varian® Carry 50 Cone model, 
dissolutor Erweka® DT 80 model, disintegrator Digimatic Cali-
per Varian® VK 100 model, durometer Varian® VK 200 model, 
friabilometer Varian®, infra-red balance Ohaus® MB 45 model, 
and an Ultrasonic Unique® Cleaner Ultrasound USC 1400 model.
Methods
The five formulations (A, B, C, D, and E) analyzed in this 
study were submitted to physical and physical-chemical tests. 
These tests were mean weight, diameter, thickness, content, 
dissolution, disintegration, hardness, friability and moisture.
Mean weight: twenty tablets/capsules of each formulation 
were individually weighed. The mean was obtained and the 
TABLE I - Samples of reference, generic and similar tablets and 
magistral capsules of carbamazepine 200.00 mg.
Carbamazepine (200.00 mg) Sample
Reference tablets (Novartis) A
Generic tablets (National Industry) B
Similar tablets (National Industry) C
Capsules (Compounding Pharmacy 1) D
Capsules (Compounding Pharmacy 2) E
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relative standard deviation (RSD) could not exceed 7.5% (for 
tablets) and 10% (for capsules) (USP). 
Diameter and Thickness: a caliper was used to measure the 
diameter and thickness of ten tablets of A, B and C samples (USP).
Content: for this test, a stock solution was prepared by 
dissolving 10 mg of carbamazepine in 100 mL of methanol and 
then a standard solution containing 10μg/mL was obtained from 
the stock solution. A test solution of the five formulations (A, 
B, C, D and E) was made at the same concentration of 10.00 
μg/mL of carbamazepine. Absorptions of these solutions were 
determined at 285 nm, using methanol as a blank. The sample 
analyzed could not contain less than 92% or more than 108% of 
carbamazepine (Farmacopéia Brasileira, 1977).
Dissolution: the dissolution medium used in this test was 
distilled water with 1% sodium sulfate lauryl (totaling 900 mL). 
Six samples of each formulation were previously weighed and 
then placed in the dissolutor. All samples were submitted to 75 
rpm on apparatus II (paddle) and 37 ± 0.5ºC temperature for 60 
minutes. After finishing this step, aliquots were collected and 
analyzed at 285 nm (Farmacopéia Brasileira, 1977).
Disintegration: this test was performed according to 
USP’s methodology. Six samples of each formulation had to 
disintegrate in less than 30 minutes (USP).
Hardness: this parameter measured the level of force 
necessary to the break the tablets. The test was performed on 
ten tablets of samples A, B and C. The results had to lie within 
a 4 to10 kilopound (Kp) range (USP).
Friability: twenty (A, B and C samples) previously wei-
ghed tablets were placed in a friabilometer with a pre-program-
med speed for five minutes. After finishing this step, samples 
were reweighed and the difference in tablet weight calculated. 
The samples could not lose more than 1.5% in weight (USP).
Moisture: twenty tablets/capsules were sprayed with 
1.5g pounds and placed in an infra-red balance which measured 
moisture content. The samples could not lose more than 5% in 
weight (USP).
RESULTS AND DISCUSSION
Tablet weight is determined by the density of the formu-
lation components and by its proportions. The USP establishes 
limits for mean weight of non-coated tablets that apply to tablets 
containing at least 50.00 mg of active substance (drug) compri-
sing more than50% of weight. Tablets which have a mean weight 
of between 80.00 and 250.00 mg may have a maximum weight 
variation of 7.5%. The results of these tests are shown in Table II.
The dimension and form of tablets are determined by the 
type of compression tool used. Thus, this parameter varies with 
the compressive load applied and must be controlled to adhere 
to a maximum variation of 5%. 
The mechanical properties of tablets can be quantified by 
friability and hardness. The friability is directly related to the 
hardness and indicates resistance to abrasion, which can occur 
inside the end packaging or during transport or manipulation. 
This parameter is important in choosing the adequate exci-
pients to prevent fast disintegration of the tablet and posterior 
dissolution of the drug before the desired time. The maximum 
loss of weight must not exceed 1.5% of tablet weight. The 
results of the friability test were 0.25%, 0.54% and 0.34% for 
samples A, B and C, respectively. These friability levels met 
USP specifications.
Hardness is an important parameter to estimate disintegra-
tion time, since resistant tablets do not disintegrate in the time 
required to satisfy the dissolution specifications. Tablets with lo-
wer hardness are unable to resist manipulation. The force needed 
to achieve tablet breakage is expressed in kilopounds (Kp). The 
values found of between 4 and 10 Kp are considered satisfactory 
for non-coated tables (oral administration). The similar presen-
tation of carbamazepine (sample C) had a hardness value greater 
than that determined by the USP (Table II). However, this result 
TABLE II - Results of hardness, diameter, thickness, mean weight, disintegration, content and moisture tests of 200.00 mg 
carbamazepine tablets and capsules.
Sample Hardness* 
(kP) ± (RSD)
Diameter* 
(mm) ± (RSD)
Thickness* 
(mm) ± (RSD)
Mean weight** 
(mg) ± (RSD)
Disintegration*** 
(min) ± (RSD)
Content****
(%) ± (RSD)
Humidity 
(%)
A 7.48 ± 1.34 9.02 ± 0.65 3.70 ± 1.19 295.52 ± 4.25 0’30’’± 0.58 96.57 ± 2.37 2.30
B 8.39 ± 0.87 9.11 ± 1.87 4.89 ± 2.17 294.02 ± 3.39 0’25’’± 3.40 98.34 ± 1.05 2.00
C 17.86 ± 2.89 11.05 ± 3.54 5.28 ± 3.89 475.49 ± 1.26 2’32’’± 4.33 101.47 ± 1.98 3.67
D - - - 261.53 ± 3.55 4’14’’± 2.35 93.14 ± 0.35 3.08
E - - - 309.72 ± 7.28 4’26’’± 1.56 94.14 ± 1.13 4.25
*n = 10; ** n = 20; ***n = 6, ****n = 3
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proved non-significant because the disintegration time within the 
30-minute limit of this formulation was considered satisfactory.
As expected, the tablet with higher hardness presented a 
longer disintegration time. However, the generic presentation, 
in spite of having a greater hardness compared to the reference 
formulation, had a shorter disintegration time. This fact may be 
due to use of crospovidone in its formulation. This excipient is 
a super disintegrate, a substance that facilitates the disintegra-
tion process, even when used in small quantities (Prista, Alves, 
Morgado, 1995).
Absorption is a parameter which depends on both di-
sintegration and dissolution parameters. Previously, only the 
disintegration was required as an indicator of a drug’s release 
parameter. However, several studies showed that the turbulent 
agitation provided by apparatus II of the disintegrator contrasts 
with the smooth and normal agitation of the gastric content du-
ring the contractions of the stomach. In addition, these studies 
revealed that the disintegrated particles do not disperse in the 
organism, but remain aggregated. Therefore, the disintegration 
test is now used only to control the variations between each 
bulk size and should not be used as a bioavailability standard 
(Guyot- Hermann, 1992).
After oral administration, the solid forms can disintegrate 
or dissolve later upon interaction with the gastrointestinal fluid. 
Hence, the speed of dissolution controls the accumulation rate 
of the drug in the blood while its kinetics provide data about the 
bioavailability of a medicine as well as its therapeutic effects in 
vivo. For this reason, this test is gaining more importance in the 
pharmaceutical industry. It is a parameter used to evaluate the 
quality of a medicine (Menegola et al., 2007).
Table III shows that all presentations analyzed met the 
USP specifications regarding the dissolution test. Dissolution 
is an important test of quality control and acts as a useful tool to 
predict bioavailability. In some cases, it can substitute clinical 
studies determining bioequivalence. The term oral bioavailability 
is defined as the fraction of the administrated drug which reaches 
the bloodstream from the gastrointestinal tract (Bosso, 2008).
When an adequate dissolution method is chosen, the dis-
solution rate of the product can be correlated with the absorption 
rate of the drug in the organism. In general, a fast dissolution rate 
results in a fast rate of appearance of the drug in blood plasma. 
Thus, correlation between the dissolution rate and absorption 
rate of the drug can be established (Shargel, Ayu, Andrew, 1999).
As outlined above, the bioavailability of a drug is defined by 
its absorption speed and extension, and is important in determining 
whether the drug reaches its target site at an effective therapeutic 
concentration (Aulton, 2005). Bioavailability can be influenced by 
the route of administration, pharmaceutical form and formulation. 
The route of administration was not relevant in this study because all 
formulations analyzed used the same route. Variability in bioavaila-
bility exhibited by a drug incorporated in different pharmaceutical 
forms, or in different formulations of the same pharmaceutical 
form, can result in higher-than-desired plasmatic concentrations, 
thereby potentiating side effects, or in lower-than-required levels, 
precluding effective therapeutic action.
The effective surface area of a drug is an important 
factor that should be correlated with its speed of dissolution, 
particularly when dealing with low solubility molecules such 
as carbamazepine. When increased effective surface area is 
ensured, the disintegration of a tablet is an important factor 
for the drug’s absorption. Should fast release, dissolution and 
consequent absorption be desired then tablets must disintegrate 
rapidly and completely in gastrointestinal fluids. The speed of 
this process is affected by the compression force applied during 
tablet production as well as by the concentration and type of drug 
and excipients (diluent, disintegrant, aggregating, lubricant and 
wetting agent).
A medicine which fulfils the requirements of the phar-
macopeia in terms of dissolution, tends to indicate safe and 
satisfactory in vivo release..
Also concerning the contact surface, the bioavailability 
of a drug administrated in a gelatin capsule can be the same or 
even better than the bioavailability of a tablet containing the 
same drug. This can be the case because the gelatin capsule 
dissolves rapidly when in contact with the gastrointestinal fluids 
and liberates its contents, which disperses rapidly and efficiently.
The ANVISA do not currently have guidelines regulating 
quality control of similar medicines or drugs produced in com-
pounding pharmacies. From this year, pharmaceutical equiva-
lence tests will be required for these drugs, where determination 
in the laboratory shall verify whether they indeed possess the 
same characteristics as the reference drug. Bioavailability will 
be assessed only from 2014 (Rumel, Nishioka, Santos, 2006).
CONCLUSION
The quality control studies for the A, B, C, D and E solid 
formulations of carbamazepine 200.00 mg were considered sa-
TABLE III – Results of dissolution test (S1 stage) of 200.00 
mg. carbamazepine tablets and capsules
Sample Maximum 
dissolution (%)
Minimum 
dissolution (%)
Mean* 
(%) ± (RSD)
A 81.15 74.50 77.84 ± 3.73
B 96.87 92.63 94.25 ± 1.70
C 105.72 96.24 104.41 ± 2.34
D 96.10 90.74 94.10 ± 2.14
E 104.40 95.18 96.39 ± 4.42
Determination of carbamazepine in pharmaceutical formulations 513
tisfactory in that they met American and Brazilian Pharmacopeia 
specifications. An exception occurred with the similar presenta-
tion, which did not meet the USP specifications. However, this 
result proved irrelevant because the disintegration time of this 
formulation was considered satisfactory.
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